Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

Celsion Corporation ($CLSN) stock climbed to its intraday high of $0.62 in the Tuesday trading session. The stock eventually closed at $0.510, up 30.77%. The company announced continued data from the fourth cohort of patients in its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company's IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with Stage III and IV ovarian cancer.
The company stated that in the first twelve patients dosed in the OVATION Study, GEN-1 plus standard chemotherapy produced impressive results, with no dose limiting toxicities and highly promising efficacy signals in this difficult to treat cancer.

Array Biopharma Inc. ($ARRY) is on the run as the stock climbed over 27% this year so far. In its Tuesday trading session, it clocked 3.40% gain. Array is a biopharma company and focuses on developing small molecular drugs for treating cancer patients.
The main catalyst for the company is its strong drug candidate portfolio. Several of its offerings are in Phase III. The prominent ones are Binimetinib, Encorafenib, and Selumetinib for the treatment of cancer. It also has ASC08/Danoprevir, a protease inhibitor for hepatitis C virus in its pipeline. According to some insiders, the company is also an attractive acquisition target.

 

• XBiotech ($XBIT) announced the publication of results from its pivotal phase 3 trial of the Company’s lead monoclonal antibody therapy MABp1 for the treatment for Advanced Colorectal Cancer.
• McKesson ($MCK) has agreed to pay $150 million to settle the dispute that it failed to properly oversee shipments of drugs, including opioid painkillers, during 2008-13.

• Benitec Biopharma's ($BNTC) announced receiving Orphan Drug designation for its BB-301. The drug is meant for the treatment of oculopharyngeal muscular dystrophy (OPMD), an inherited disorder.
• Allergan ($AGN) announced that a second Phase 3 clinical trial, Venus II, assessing Gedeon Richter's ulipristal acetate in women with abnormal bleeding due to uterine fibroids, met all co-primary and secondary endpoints compared to placebo.

 
• Biogen ($BIIB) will collaborate with Siemens for developing MRI applications with the intent of quantifying key markers of multiple sclerosis disease activity and progression.
• Agenus ($AGEN) announced its new clinical collaboration with the National Cancer Institute to evaluate the combination of Prophage (HSPPC-96) and Merck's ($MRK) KEYTRUDA (pembrolizumab) in patients with newly diagnosed glioblastoma.

• Natera ($NTRA) receives Buy rating from Canaccord Genuity. The price target for the stock has been set at $18 apiece.
• Agios Pharmaceuticals ($AGIO) receives Outperform rating from Oppenheimer. The price target for the stock has been set at $75 apiece.

Gainers (% price change) Last Trade Change Mkt Cap
ImmunoGen, Inc.
IMGN (NASDAQ) 2.56 +0.13 (5.35%) 220.77M
Tenet Healthcare Corp
THC (NYSE)
18.99 +0.77 (4.23%) 1.91B
LifePoint Health Inc
LPNT (NASDAQ) 61.35 +2.15 (3.63%) 2.47B
Array Biopharma Inc
ARRY (NASDAQ) 11.24 +0.37 (3.40%) 2.04B
Antares Pharma Inc
ATRS (NASDAQ) 2.15 +0.06 (2.87%) 316.76M
Losers (% price change)
Amicus Therapeutics, Inc.
FOLD (NASDAQ) 5.41 -0.54 (-9.08%) 819.57M
Alnylam Pharmaceuticals
ALNY (NASDAQ)
38.22 -3.38 (-8.12%) 3.26B
NewLink Genetics Corp
NLNK (NASDAQ) 11.11 -0.91 (-7.57%) 325.85M
Cytokinetics, Inc.
CYTK (NASDAQ) 11.00 -0.85 (-7.17%) 449.48M
Momenta Pharmaceuticals
MNTA (NASDAQ) 15.00 -1.10 (-6.83%) 1.09B
Most Actives (dollar volume)
Pfizer Inc.
PFE (NYSE)
32.06 -0.46 (-1.41%) 194.07B
UnitedHealth Group Inc
UNH (NYSE)
160.66 -1.14 (-0.70%) 152.39B
Gilead Sciences, Inc.
GILD (NASDAQ)
71.91 -1.16 (-1.59%) 94.36B
Johnson & Johnson
JNJ (NYSE)
114.87 +0.27 (0.24%) 312.45B
Merck & Co., Inc.
MRK (NYSE)
61.48 -0.86 (-1.38%) 169.86B